DK0779810T3 - Anvendelse af ketoconazol og beslægtede stoffer i medikamenter til behandling af type II-diabetes - Google Patents

Anvendelse af ketoconazol og beslægtede stoffer i medikamenter til behandling af type II-diabetes

Info

Publication number
DK0779810T3
DK0779810T3 DK94927881T DK94927881T DK0779810T3 DK 0779810 T3 DK0779810 T3 DK 0779810T3 DK 94927881 T DK94927881 T DK 94927881T DK 94927881 T DK94927881 T DK 94927881T DK 0779810 T3 DK0779810 T3 DK 0779810T3
Authority
DK
Denmark
Prior art keywords
ketoconazole
diabetes
drugs
type
treatment
Prior art date
Application number
DK94927881T
Other languages
English (en)
Inventor
Per Marin
Original Assignee
Cortendo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortendo Ab filed Critical Cortendo Ab
Application granted granted Critical
Publication of DK0779810T3 publication Critical patent/DK0779810T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65BMACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B1/00Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B1/04Methods of, or means for, filling the material into the containers or receptacles
    • B65B1/08Methods of, or means for, filling the material into the containers or receptacles by vibratory feeders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Mechanical Engineering (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK94927881T 1994-08-09 1994-08-09 Anvendelse af ketoconazol og beslægtede stoffer i medikamenter til behandling af type II-diabetes DK0779810T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SE1994/000729 WO1996004912A1 (en) 1994-08-09 1994-08-09 Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes

Publications (1)

Publication Number Publication Date
DK0779810T3 true DK0779810T3 (da) 2003-10-20

Family

ID=20393155

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94927881T DK0779810T3 (da) 1994-08-09 1994-08-09 Anvendelse af ketoconazol og beslægtede stoffer i medikamenter til behandling af type II-diabetes

Country Status (14)

Country Link
US (2) US5849740A (da)
EP (2) EP0779810B8 (da)
JP (1) JP3825469B2 (da)
KR (1) KR100422162B1 (da)
AT (1) ATE244009T1 (da)
CA (1) CA2196174C (da)
CZ (1) CZ285290B6 (da)
DE (1) DE69432905T2 (da)
DK (1) DK0779810T3 (da)
ES (1) ES2202326T3 (da)
NO (1) NO314616B1 (da)
PT (1) PT779810E (da)
SI (1) SI0779810T1 (da)
WO (1) WO1996004912A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642236B1 (en) * 1998-12-14 2003-11-04 Cortendo Ab Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
SI0779810T1 (en) * 1994-08-09 2003-12-31 Cortendo Ab Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
SE9700642D0 (sv) * 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
AU2002365122A1 (en) * 2001-08-23 2003-07-15 New England Biolabs, Inc. A method for engineering strand-specific, sequence-specific, dna-nicking enzymes
ES2346961T3 (es) 2001-11-22 2010-10-22 Biovitrum Ab Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
EP2053409A1 (en) 2003-11-20 2009-04-29 F. Hoffmann-La Roche Ag Specific markers for metabolic syndrome
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
ZA200706020B (en) * 2005-01-10 2008-12-31 Cortendo Invest Ab Publ Methods and compositions for treating diabetes, metabolic syndrome and other conditions
US20100280046A1 (en) * 2006-01-10 2010-11-04 Diobex, Inc. Methods and Compositions for Treating Prostate Cancer, Benign Prostatic Hypertrophy, Polycystic Ovary Syndrome and Other Conditions
JP2006206605A (ja) * 2006-03-29 2006-08-10 Metabolic Syndrome I Goeteborg Ab 代謝性症候群の治療薬
EP1886695A1 (en) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
CA2664800A1 (en) 2006-10-02 2008-04-10 Timothy Andrew Stewart Ketoconazole enantiomer in humans
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432176A (en) * 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
US5175144A (en) * 1988-11-29 1992-12-29 The Johns Hopkins University Method of retarding the progression of chronic renal failure
SI0779810T1 (en) * 1994-08-09 2003-12-31 Cortendo Ab Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
US5591736A (en) * 1995-07-03 1997-01-07 The Johns Hopkins University Method of retarding the progression of chronic renal failure

Also Published As

Publication number Publication date
SI0779810T1 (en) 2003-12-31
JP3825469B2 (ja) 2006-09-27
KR100422162B1 (ko) 2004-07-07
US6166017A (en) 2000-12-26
JPH10510241A (ja) 1998-10-06
AU695011B2 (en) 1998-08-06
EP1360960A1 (en) 2003-11-12
EP0779810B8 (en) 2003-09-17
EP0779810A1 (en) 1997-06-25
CA2196174A1 (en) 1996-02-22
DE69432905D1 (de) 2003-08-07
AU7711894A (en) 1996-03-07
ES2202326T3 (es) 2004-04-01
NO970567L (no) 1997-02-07
DE69432905T2 (de) 2004-05-27
US5849740A (en) 1998-12-15
NO314616B1 (no) 2003-04-22
KR970704440A (ko) 1997-09-06
ATE244009T1 (de) 2003-07-15
CZ36097A3 (en) 1997-06-11
CZ285290B6 (cs) 1999-06-16
PT779810E (pt) 2003-11-28
NO970567D0 (no) 1997-02-07
CA2196174C (en) 2005-03-01
WO1996004912A1 (en) 1996-02-22
EP0779810B1 (en) 2003-07-02

Similar Documents

Publication Publication Date Title
DK0779810T3 (da) Anvendelse af ketoconazol og beslægtede stoffer i medikamenter til behandling af type II-diabetes
CY1107752T1 (el) Xρηση των εξενδινων και αγωνιστων τους για τη θεραπεια του σακχαρωδους διαβητη της κυησης
NO995932D0 (no) Anvendelse av tiazolidindion-derivater i behandling av polycystiske ovariesyndrom og svangerskapsdiabetes
CY1106791T1 (el) Συνδυασμοι αναστολεα (-ων) απορροφησης στερολης με καρδιαγγειακο παραγοντα (-ες) για τη θεραπεια αγγειακων καταστασεων
NO20010982L (no) Fremgangsmåte for å administrere insulinotropiske peptider
CY1110894T1 (el) Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης
DE60042598D1 (de) Medikamente zur behandlung des syndroms der chronishen ermüdung, das mit fibromyalgie und reizdarm assoziert ist.
NO20041203L (no) Human glukagonlignende peptid-1 etterligner og deres anvendelse i behandling av diabetes og relaterte tilstander.
MXPA02007099A (es) Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina.
PT1143955E (pt) Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
NO20075695L (no) Fremgangsmate til a behandle eller forhindre type-2 diabetes
DE60037032D1 (de) Anwendung von pdt zur inhibierung von hyperplasie der intima
JP2003528919A5 (da)
WO2004028453A3 (en) Methods for preventing and treating obesity in patients with mc4 receptor mutations
EP1757302A8 (en) Adiponectin expression inducer and utilization of the same
WO2005053728A3 (de) Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
PL334498A1 (en) Application of pramiprexole in treating the restless legs syndrome
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
DE69909636D1 (de) Verwendung von methoxymorpholino doxorubicin zur behandlung eines lebertumor
Cetik et al. Contrary intermittent skin release of complete syndactyly without skin graft in adults
WO2004064855A8 (de) Medikament und verwendung zur tumortherapie
EP1274452A4 (en) METHOD FOR PREVENTING AND TREATING DIABETES
UA32255A (uk) Спосіб лікування цукрового діабету
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
ATE271878T1 (de) Verwendung von protein h als zytostattischer wirkstoff